Skip to main content
. 2018 Jun 2;30(8):375–383. doi: 10.1093/intimm/dxy040

Fig. 4.

Fig. 4.

ATRA synergizes with DARA to impede AML tumor growth. (A, B) NSG mice were subcutaneously injected with 2.5 × 106 MV4-11 cells and treated with vehicle (untreated), ATRA, DARA or the combination of ATRA and Daratumumab (n = 6 per group). (A) Tumor growth rate was compared between the combination of ATRA + DARA and vehicle control (untreated), ATRA alone and DARA alone (P values: <0.0001, <0.0001 and 0.0048, respectively). An interaction test for synergistic effects between ATRA and DARA was also done (P = 0.0364, denoted by vertical line and asterisk). (B) Photographs of excised tumors. Note: Mouse #5 in the ATRA group died of disease prior to study conclusion; tumor size was recorded at the time of death (day 17). (C) NSG mice were intravenously injected with 3.0 × 105 spleen cells from MV4-11-engrafted mice and treated with vehicle (untreated), ATRA, Daratumumab or the combination of ATRA and Daratumumab (n = 18 mice per group). Survival was compared between ATRA + Daratumumab group versus untreated, ATRA and Daratumumab groups, respectively (log-rank P values were 0.0030, 0.0004 and 0.0122, respectively). *P ≤ 0.05.